Edoc Acquisition Corp. Class A Ordinary Share (ADOC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADOC Stock Price Chart Interactive Chart >
ADOC Price/Volume Stats
|Current price||$10.20||52-week high||$11.60|
|Prev. close||$10.20||52-week low||$10.00|
|Day high||$10.20||Avg. volume||37,769|
|50-day MA||$10.19||Dividend yield||N/A|
|200-day MA||$10.13||Market Cap||55.87M|
Most Popular Stories View All
ADOC Latest News Stream
|Loading, please wait...|
ADOC Latest Social Stream
View Full ADOC Social Stream
Latest ADOC News From Around the Web
Below are the latest news stories about Edoc Acquisition Corp that investors may wish to consider to help them evaluate ADOC as an investment opportunity.
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a shareholder rights law firm, announces it is investigating the following companies concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to: Edoc Acquisition Corp. (NASDAQ: ADOC )''s merger with Calidi Biotherapeutics, Inc. If you are an Edoc shareholder, click here to learn more about your rights and options . CHW Acquisition Corporation (NASDAQ: CHWA )''s merger with Wag Labs, Inc. If you are a CHWA shareholder, click here to learn more about your rights and options . Partners Bancorp (NASDAQ: PTRS )''s sale to OceanFirst Financial Corp. Under Full story available on Benzinga.com
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, and ADOCW) (“Edoc” or the “Company”) encourages its shareholders to vote in favor of the proposal to amend its charter (the “Extension Amendment”) to extend the date by which the Company has to complete a business combination from February 12, 2022 to August 12, 2022 (the “Extension”). An extraordinary general meeting of the Company’s shareholders (“Special Meeting”) to approve the Extension Amendment will b
Calidi Biotherapeutics agreed to go public through a deal with Edoc Acquisition Corp
Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
-Total gross proceeds from transaction expected to be approximately $117 million prior to redemptions, combining $25 million PIPE and up to $92 million held in Edoc trust account- -Anticipated cash resources will fund Calidi’s NeuroNova and SuperNova development programs through multiple clinical milestones- -Business combination expected to be completed in second quarter of 2022- LA JOLLA, CALIF. and Victor, NY, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Co
Victor, NY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (NASDAQ: ADOC) (the “Company”), announced today that an aggregate of $900,000 (the “Extension Payment”) has been deposited into the Company’s trust account for its public shareholders, representing $0.10 per public share, which enables the Company to extend the period of time it has to consummate its initial business combination by three months from November 12, 2021 to February 12, 2022 (the “Extension”). The Extension is the first of up to two three-month extensions permitted under the Company’s governing documents.
ADOC Price Returns